Court Enjoins Sandoz’s Generic Mirapex; No Sale of Generic Until Early October

Judge Timothy J. Corrigan of the U.S. District Court for the Middle District of Florida July 29 signed off on an order under which generic drugmaker Sandoz Inc. agreed not to market a generic version of Boehringer Ingelheim International GMBH’s Parkinson’s disease treatment Mirapex (pramipexole dihydrochloride), until after Boehringer’s patent on the drug expires in early October (Sandoz Inc. v. Boehringer Ingelheim International GMBH).

The stipulation was entered shortly after Corrigan ruled from the bench July 26 that Sandoz would be preliminarily enjoined from marketing its generic until the patent at issue—Boehringer’s U.S. Patent No. 4,886,812— expired Oct. ...